Biocon Biologics India Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Biocon Biologics India Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $7.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biocon Biologics India Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $7.8M Trade | TransData Nexus

Biocon Biologics India Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $7.8M Total Trade · DGFT Verified

Biocon Biologics India Limited is an Indian pharmaceutical exporter with a total trade value of $7.8M across 5 products in 4 therapeutic categories. Based on 158 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ras ($3.2M), Bevacizumab ($2.3M), Trastuzumab ($1.9M).

Biocon Biologics India Limited — Export Portfolio & Destination Treemap

Biocon Biologics India Limited pharmaceutical export portfolio — 5 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Biocon Biologics India Limited? — Company Overview & Market Position

Biocon Biologics India Limited, a subsidiary of Biocon Limited, is a global leader in the development and commercialization of high-quality, affordable biosimilars. Established on June 8, 2016, with Corporate Identification Number (CIN) U24119KA2016FLC093936, the company is headquartered in Bengaluru, Karnataka, India. Biocon Limited, the parent company, is a publicly listed biopharmaceutical enterprise founded in 1978 by Kiran Mazumdar-Shaw. Biocon Biologics operates as an independent entity with its own dedicated management, focusing on biosimilars across therapeutic areas such as diabetes, oncology, and immunology.

As of March 2023, Biocon Limited employed approximately 16,545 individuals, reflecting its expansive operations and commitment to innovation in the biopharmaceutical sector. The company's official website, www.bioconbiologics.com, provides comprehensive information about its products, services, and corporate initiatives.

What Does Biocon Biologics India Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ras$3.2M 2

Product Portfolio — Top 5 by Export Value

Biocon Biologics India Limited exports 5 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ras	Ayurvedic & Herbal Products	$3.2M	64	1.0%	5
2	Bevacizumab	Advanced Oncology	$2.3M	46	4.9%	2
3	Trastuzumab	Advanced Oncology	$1.9M	39	2.5%	2
4	Insulin	Diabetes & Endocrine	$200.0K	4	0.3%	12
5	Ustekinumab	Biologics & Immunotherapy	$160.7K	5	12.6%	3

Biocon Biologics India Limited exports 5 pharmaceutical products across 4 therapeutic categories with a total export value of $7.8M. The top category is Advanced Oncology (54.4% of portfolio), followed by Ayurvedic & Herbal Products (41.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Biocon Biologics India Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Biocon Biologics operates state-of-the-art manufacturing facilities in Bengaluru, India, and Johor, Malaysia, designed to meet stringent cGMP guidelines and international regulatory standards. These facilities encompass large-scale microbial fermentation, mammalian cell culture, protein and antibody purification, aseptic formulation, and fill-finish processes. The Bengaluru campus, spanning approximately 90 acres, is approved by regulatory agencies such as the USFDA, EMA, COFEPRIS, and KFDA, and specializes in APIs derived from fermentation, synthetic chemistry, peptides, HPAPIs, and oral solid formulations. The Johor facility further extends Biocon Biologics' global manufacturing capabilities, supporting its expansive biosimilars portfolio.

3Key Leadership

Biocon Biologics is led by a team of seasoned professionals committed to advancing the company's mission. Shreehas P. Tambe serves as the Chief Executive Officer and Managing Director, overseeing the company's strategic direction and operations. Siddharth Mittal, the CEO and Managing Director of Biocon Limited, provides overarching leadership to the group. Kiran Mazumdar-Shaw, the Executive Chairperson of Biocon Limited, offers strategic guidance and vision. Peter Bains, the Group CEO, brings extensive experience in the biopharmaceutical industry, contributing to the company's global expansion and innovation initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Biocon Biologics India Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Biocon Biologics has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has commercialized multiple biosimilars in these regions, such as Trastuzumab, Pegfilgrastim, Bevacizumab, recombinant human Insulin, and Insulin Glargine. In May 2024, Biocon Biologics received FDA approval for its first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable biosimilar of aflibercept. This approval underscores the company's commitment to expanding access to affordable biologic therapies in advanced markets.

2Emerging Markets

Biocon Biologics has made significant inroads into emerging markets, including Africa, Latin America, and Southeast Asia. The company's portfolio of biosimilars has been commercialized in over 100 countries, addressing the healthcare needs of diverse populations. The World Health Organization's prequalification of Biocon Biologics' products has facilitated access to these markets, ensuring that patients benefit from high-quality, affordable biosimilars.

3Geographic Strategy

Biocon Biologics India Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Biocon Biologics has achieved significant milestones with the U.S. Food and Drug Administration (FDA). The company has received approvals for multiple biosimilars, including Trastuzumab, Pegfilgrastim, and Insulin Glargine. In May 2024, Biocon Biologics received FDA approval for its first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable biosimilar of aflibercept. These approvals reflect the company's commitment to meeting the rigorous standards set by the FDA and expanding access to affordable biologic therapies in the U.S. market.

2WHO & EU GMP

Biocon Biologics' manufacturing facilities adhere to Good Manufacturing Practice (GMP) standards set by the World Health Organization (WHO) and the European Union (EU). The company's facilities in Bengaluru, India, and Johor, Malaysia, are designed to meet stringent cGMP guidelines and comply with international regulatory standards. These certifications ensure that Biocon Biologics' products meet the highest quality standards, facilitating access to global markets.

3CDSCO & Indian Regulatory

Biocon Biologics India Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Biocon Biologics operates in a competitive landscape with several key players in the biosimilars market. Notable competitors include Sandoz, Celltrion, and Samsung Bioepis, which also offer biosimilars across various therapeutic areas. Biocon Biologics differentiates itself through its expansive portfolio, including recombinant human Insulin, Insulin Glargine, Trastuzumab, and Pegfilgrastim, and its global manufacturing capabilities. The company's strategic focus on affordability and access positions it favorably in the global biosimilars market.

2Key Differentiators

Biocon Biologics' key differentiators include its fully integrated biosimilars portfolio, spanning insulins, monoclonal antibodies, and conjugated recombinant proteins. The company's manufacturing facilities in Bengaluru, India, and Johor, Malaysia, are designed to meet stringent cGMP guidelines and comply with international regulatory standards. Additionally, Biocon Biologics' commitment to affordability and access to healthcare solutions sets it apart in the biopharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Biocon Biologics India Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Biocon Biologics has a strong track record in the biopharmaceutical industry, with a focus on developing high-quality, affordable biosimilars. The company's manufacturing facilities in Bengaluru, India, and Johor, Malaysia, are designed to meet stringent cGMP guidelines and comply with international regulatory standards. Biocon Biologics' commitment to quality and compliance, along with its expansive portfolio and global manufacturing capabilities, make it a reliable supplier in the biosimilars market.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Biocon Biologics India Limited

How many pharmaceutical products does Biocon Biologics India Limited export from India?

Biocon Biologics India Limited exports 5 pharmaceutical products across 4 therapeutic categories. The top exports are Ras ($3.2M), Bevacizumab ($2.3M), Trastuzumab ($1.9M), Insulin ($200.0K), Ustekinumab ($160.7K). Total export value is $7.8M.

What is Biocon Biologics India Limited's total pharmaceutical export value?

Biocon Biologics India Limited's total pharmaceutical export value is $7.8M, based on 158 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Biocon Biologics India Limited cover?

Biocon Biologics India Limited exports across 4 therapeutic categories. The largest are Advanced Oncology (54.4%, 2 products), Ayurvedic & Herbal Products (41.0%, 1 products), Diabetes & Endocrine (2.6%, 1 products).

Get Full Biocon Biologics India Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.